Extended Data Fig. 13 |. In vivo degradation of Siglec-7/9 in tumor-infiltrating immune cells in Sig7/9⁺ mice.

a, Flow cytometry analysis of Siglec-7/9 ligand (8^bio) tetramer binding to peripheral blood CD11b⁺ cells from WT mice in comparison with anti-Siglec-E (clone M1304A01) staining. b, Gating strategy for sorting tumor-infiltrating myeloid cells in B16-GMCSF tumors inoculated in Sig7/9⁺ mice, in which, DCs, M-MDSCs, PMN-MDSCs and TAMs were characterized among CD45.2⁺CD11b⁺ population after gating out doublets and dead cells. DC, dendritic cell; M-MDSC, monocytic myeloid-derived suppressor cell; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; TAM, tumor-associated macrophage. c,d, Assessment of in vivo Siglec-7/-9 depletion in tumor and tumor dLN-infiltrating NK cells following administration of 10 μg Sig7/9de or PBS to B16-GMCSF tumor-bearing Sig7/9⁺ mice for 2 days. NK, natural killer. Data are mean ± s.d. Two-tailed unpaired Student’s t-test (c,d).